BMY/PFE—Eliquis grew 40%(!) YoY in 2Q18 and is now selling at an annualized rate of $6.6B. (BMY books all of the Eliquis sales, but PFE owns 60% of the worldwide profit share.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”